Cargando…

Global Proteome Changes in Liver Tissue 6 Weeks after FOLFOX Treatment of Colorectal Cancer Liver Metastases

(1) Oxaliplatin-based chemotherapy for colorectal cancer liver metastasis is associated with sinusoidal injury of liver parenchyma. The effects of oxaliplatin-induced liver injury on the protein level remain unknown. (2) Protein expression in liver tissue was analyzed—from eight patients treated wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Urdzik, Jozef, Vildhede, Anna, Wiśniewski, Jacek R., Duraj, Frans, Haglund, Ulf, Artursson, Per, Norén, Agneta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260963/ https://www.ncbi.nlm.nih.gov/pubmed/28248240 http://dx.doi.org/10.3390/proteomes4040030

Ejemplares similares

Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug Interactions
por: Karlgren, Maria, et al.
Publicado: (2012)

Influence of Proteome Profiles and Intracellular Drug Exposure on Differences in CYP Activity in Donor-Matched Human Liver Microsomes and Hepatocytes
por: Wegler, Christine, et al.
Publicado: (2021)

Composite Score: prognostic tool to predict survival in patients undergoing surgery for colorectal liver metastases
por: Frühling, Petter, et al.
Publicado: (2021)

FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer
por: Bertolini, F, et al.
Publicado: (2011)

Outcomes of Simultaneous Resections and Classical Strategy for Synchronous Colorectal Liver Metastases in Sweden: A Nationwide Study with Special Reference to Major Liver Resections
por: Valdimarsson, Valentinus T., et al.
Publicado: (2020)

Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer
por: Mehrzad, Valiollah, et al.
Publicado: (2016)

Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
por: Takahashi, Takao, et al.
Publicado: (2022)

Conversion to resectability using transcatheter arterial chemoembolization alternating with mFOLFOX6 in patients with colorectal liver metastases
por: Wang, Shuai, et al.
Publicado: (2019)

Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.
por: Twelves, C. J., et al.
Publicado: (1989)

Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6
por: Barve, Vedin, et al.
Publicado: (2021)

Drug Disposition Protein Quantification in Matched Human Jejunum and Liver From Donors With Obesity
por: Wegler, Christine, et al.
Publicado: (2022)

Stereology: a novel technique for rapid assessment of liver volume
por: Torkzad, Michael R., et al.
Publicado: (2012)

Proteome deconvolution of liver biopsies reveals hepatic cell composition as an important marker of fibrosis
por: Handin, Niklas, et al.
Publicado: (2023)

Proteomic Profiling and Biomarker Discovery in Colorectal Liver Metastases
por: Wong, Geoffrey Yuet Mun, et al.
Publicado: (2022)

Prognostic circulating proteomic biomarkers in colorectal liver metastases
por: Kim, Dongchan, et al.
Publicado: (2023)

Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy
por: James, Mark I., et al.
Publicado: (2015)

KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary
por: Vauthey, J-N, et al.
Publicado: (2012)

The Resection Rate of Synchronously Detected Liver and Lung Metastasis from Colorectal Cancer Is Low—A National Registry-Based Study
por: Engstrand, Jennie, et al.
Publicado: (2023)

Global variability analysis of mRNA and protein concentrations across and within human tissues
por: Wegler, Christine, et al.
Publicado: (2019)

Conditions for maintenance of hepatocyte differentiation and function in 3D cultures
por: Handin, Niklas, et al.
Publicado: (2021)

Early Identification of Clinically Relevant Drug Interactions With the Human Bile Salt Export Pump (BSEP/ABCB11)
por: Pedersen, Jenny M., et al.
Publicado: (2013)

A 5-year recurrence-free survivor with over ten colorectal liver metastases undergoing FOLFOX plus bevacizumab followed by two-stage hepatectomy
por: Tamaoki, Yuka, et al.
Publicado: (2015)

Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors
por: Gabrovska, M, et al.
Publicado: (2009)

Proteome biology of primary colorectal carcinoma and corresponding liver metastases
por: Fahrner, Matthias, et al.
Publicado: (2021)

Proteomics‐Informed Prediction of Rosuvastatin Plasma Profiles in Patients With a Wide Range of Body Weight
por: Wegler, Christine, et al.
Publicado: (2020)

Reply: KRAS mutation in colorectal cancer metastases after adjuvant folfox for the primary
por: Yoshino, T, et al.
Publicado: (2012)

Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study
por: Gibbs, Peter, et al.
Publicado: (2014)

Liver Resection for Non-Colorectal Liver Metastases – Standards and Extended Indications
por: Kulik, Ulf, et al.
Publicado: (2015)

Proteomic Profiling of Chemotherapy Responses in FOLFOX-Resistant Colorectal Cancer Cells
por: Tam, Shing-Yau, et al.
Publicado: (2023)

Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report
por: Malavasi, Norma, et al.
Publicado: (2009)

Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study
por: Pernot, Simon, et al.
Publicado: (2020)

Liver Graft Proteomics Reveals Potential Incipient Mechanisms behind Early Renal Dysfunction after Liver Transplantation
por: Norén, Åsa, et al.
Publicado: (2022)

Proteomes: A New Proteomic Journal
por: Wiśniewski, Jacek R.
Publicado: (2012)

Perioperative FOLFOX in management of peritoneal metastases of colorectal cancer. Case report of 2 patients
por: Sugarbaker, Paul H., et al.
Publicado: (2020)

Future Liver Remnant (FLR) Increase in Patients with Colorectal Liver Metastases Is Highest the First Week After Portal Vein Occlusion: FLR Increase in Patients with CRLM Is Highest the First Week After PVO
por: Hasselgren, Kristina, et al.
Publicado: (2018)

Surgical management of neuroendocrine tumour (NET) liver metastases
por: Hellman, Per
Publicado: (2013)

Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
por: Oki, Eiji, et al.
Publicado: (2019)

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
por: Nordlinger, Bernard, et al.
Publicado: (2008)

Proteomics analysis of the matrisome from MC38 experimental mouse liver metastases
por: Yuzhalin, Arseniy E., et al.
Publicado: (2019)

Colorectal Liver Metastases
por: Haddad, Ashraf J., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_dbsn97askqcajeviauvgd4891c